CAR T therapy beyond cancer: the evolution of a living drug
Engineering a patient's own T cells to selectively target and eliminate tumour cells has cured
patients with untreatable haematologic cancers. These results have energized the field to …
patients with untreatable haematologic cancers. These results have energized the field to …
From bench to bedside: the history and progress of CAR T cell therapy
Chimeric antigen receptor (CAR) T cell therapy represents a major breakthrough in cancer
care since the approval of tisagenlecleucel by the Food and Drug Administration in 2017 for …
care since the approval of tisagenlecleucel by the Food and Drug Administration in 2017 for …
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
SM Albelda - Nature Reviews Clinical Oncology, 2024 - nature.com
Chimeric antigen receptor (CAR) T cells have been approved for use in patients with B cell
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …
[HTML][HTML] Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity
Chimeric antigen receptor (CAR) T cell therapy effectively treats human cancer, but the loss
of the antigen recognized by the CAR poses a major obstacle. We found that in vivo vaccine …
of the antigen recognized by the CAR poses a major obstacle. We found that in vivo vaccine …
Forks in the road for CAR T and CAR NK cell cancer therapies
OK Dagher, AD Posey Jr - Nature Immunology, 2023 - nature.com
The advent of chimeric antigen receptor (CAR) T cell therapy has resulted in unprecedented
long-term clearance of relapse/refractory hematological malignancies in both pediatric and …
long-term clearance of relapse/refractory hematological malignancies in both pediatric and …
[HTML][HTML] Cancer Focus: CAR-T cell manufacturing: Major process parameters and next-generation strategies
MA Ceja, M Khericha, CM Harris… - The Journal of …, 2024 - ncbi.nlm.nih.gov
Chimeric antigen receptor (CAR)-T cell therapies have demonstrated strong curative
potential and become a critical component in the array of B-cell malignancy treatments …
potential and become a critical component in the array of B-cell malignancy treatments …
Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells
SM Reincke, N von Wardenburg, MA Homeyer… - Cell, 2023 - cell.com
Anti-NMDA receptor (NMDAR) autoantibodies cause NMDAR encephalitis, the most
common autoimmune encephalitis, leading to psychosis, seizures, and autonomic …
common autoimmune encephalitis, leading to psychosis, seizures, and autonomic …
Targeted nonviral delivery of genome editors in vivo
CA Tsuchida, KM Wasko… - Proceedings of the …, 2024 - National Acad Sciences
Cell-type-specific in vivo delivery of genome editing molecules is the next breakthrough that
will drive biological discovery and transform the field of cell and gene therapy. Here, we …
will drive biological discovery and transform the field of cell and gene therapy. Here, we …
A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells
CRISPR technologies have begun to revolutionize T cell therapies; however, conventional
CRISPR-Cas9 genome-editing tools are limited in their safety, efficacy, and scope. To …
CRISPR-Cas9 genome-editing tools are limited in their safety, efficacy, and scope. To …
CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes
S Jilani, JD Saco, E Mugarza, A Pujol-Morcillo… - Nature …, 2024 - nature.com
A major limitation to developing chimeric antigen receptor (CAR)-T cell therapies for solid
tumors is identifying surface proteins highly expressed in tumors but not in normal tissues …
tumors is identifying surface proteins highly expressed in tumors but not in normal tissues …